Production of 230Pa by proton irradiation of 232Th at the LANL isotope production facility: Precursor of 230U for targeted alpha therapy

Friend, Mitchell Thomas; Mastren, Tara; Parker, Tracey Gannon; Vermeulen, Christiaan E.; Brugh, Mark; Birnbaum, Eva R.; Nortier, Francios Meiring; Fassbender, Michael Ernst

doi:10.1016/j.apradiso.2019.108973

Title: Production of ²³⁰Pa by proton irradiation of ²³²Th at the LANL isotope production facility: Precursor of ²³⁰U for targeted alpha therapy

Full Record
Other Related Research

Abstract

Uranium-230 (t_1/2 = 20.8 d) is an alpha-emitting radionuclide that has potential application in targeted alpha therapy (TAT) of cancer. Its parent isotope ²³⁰Pa (t_1/2 = 17.4 d), can be produced by proton irradiation of thorium metal targets. Preliminary ²³⁰Pa production runs were performed at the Los Alamos National Laboratory Isotope Production Facility (LANL-IPF) using thin thorium metal targets and a proton beam energy of 15–30 MeV, followed by radiochemical separation of ²³⁰Pa from the irradiated target matrix. The measured ²³⁰Pa production yields were found to exceed the predicted values in most of the experiments that were performed. Furthermore, this data will inform further production efforts for providing ²³⁰Pa/²³⁰U for clinical trials.

Authors:

^[1];

^[2]; Parker, Tracey Gannon ^[1];

^[1]; Brugh, Mark ^[1];

^[1];

^[1]

Los Alamos National Lab. (LANL), Los Alamos, NM (United States). Chemistry Div.
Univ. of Utah, Salt Lake City, UT (United States). Nuclear Engineering Program, Dept. of Civil and Environmental Engineering; Los Alamos National Lab. (LANL), Los Alamos, NM (United States). Chemistry Div.

Publication Date:: Tue Nov 05 00:00:00 EST 2019

Research Org.:: Los Alamos National Laboratory (LANL), Los Alamos, NM (United States)

Sponsoring Org.:: USDOE Office of Science (SC), Nuclear Physics (NP)

OSTI Identifier:: 1574001

Alternate Identifier(s):: OSTI ID: 1596158

Report Number(s):: LA-UR-19-28727
Journal ID: ISSN 0969-8043; TRN: US2001112

Grant/Contract Number:: 89233218CNA000001; FOA LAB 14-1099

Resource Type:: Accepted Manuscript

Journal Name:: Applied Radiation and Isotopes

Additional Journal Information:: Journal Volume: 156; Journal ID: ISSN 0969-8043

Publisher:: Elsevier

Country of Publication:: United States

Language:: English

Subject:: 07 ISOTOPE AND RADIATION SOURCES; Protactinium-230; Uranium-230; Thorium-226; Proton irradiation; Isotope production; Targeted alpha therapy

Citation Formats


                    Friend, Mitchell Thomas, Mastren, Tara, Parker, Tracey Gannon, Vermeulen, Christiaan E., Brugh, Mark, Birnbaum, Eva R., Nortier, Francios Meiring, and Fassbender, Michael Ernst. Production of 230Pa by proton irradiation of 232Th at the LANL isotope production facility: Precursor of 230U for targeted alpha therapy.  United States: N. p., 2019. 
Web.  doi:10.1016/j.apradiso.2019.108973.

Copy to clipboard


                    Friend, Mitchell Thomas, Mastren, Tara, Parker, Tracey Gannon, Vermeulen, Christiaan E., Brugh, Mark, Birnbaum, Eva R., Nortier, Francios Meiring, & Fassbender, Michael Ernst. Production of 230Pa by proton irradiation of 232Th at the LANL isotope production facility: Precursor of 230U for targeted alpha therapy.  United States.  https://doi.org/10.1016/j.apradiso.2019.108973

Copy to clipboard


                    Friend, Mitchell Thomas, Mastren, Tara, Parker, Tracey Gannon, Vermeulen, Christiaan E., Brugh, Mark, Birnbaum, Eva R., Nortier, Francios Meiring, and Fassbender, Michael Ernst. Tue .  
"Production of 230Pa by proton irradiation of 232Th at the LANL isotope production facility: Precursor of 230U for targeted alpha therapy".  United States.  https://doi.org/10.1016/j.apradiso.2019.108973.  https://www.osti.gov/servlets/purl/1574001.

Copy to clipboard


                    
@article{osti_1574001,

  title        = {Production of 230Pa by proton irradiation of 232Th at the LANL isotope production facility: Precursor of 230U for targeted alpha therapy},

  author       = {Friend, Mitchell Thomas and Mastren, Tara and Parker, Tracey Gannon and Vermeulen, Christiaan E. and Brugh, Mark and Birnbaum, Eva R. and Nortier, Francios Meiring and Fassbender, Michael Ernst},

  abstractNote = {Uranium-230 (t1/2 = 20.8 d) is an alpha-emitting radionuclide that has potential application in targeted alpha therapy (TAT) of cancer. Its parent isotope 230Pa (t1/2 = 17.4 d), can be produced by proton irradiation of thorium metal targets. Preliminary 230Pa production runs were performed at the Los Alamos National Laboratory Isotope Production Facility (LANL-IPF) using thin thorium metal targets and a proton beam energy of 15–30 MeV, followed by radiochemical separation of 230Pa from the irradiated target matrix. The measured 230Pa production yields were found to exceed the predicted values in most of the experiments that were performed. Furthermore, this data will inform further production efforts for providing 230Pa/230U for clinical trials.},

  doi          = {10.1016/j.apradiso.2019.108973},

  journal      = {Applied Radiation and Isotopes},

  number       = ,

  volume       = 156,

  place        = {United States},

  year         = {Tue Nov 05 00:00:00 EST 2019},

  month        = {Tue Nov 05 00:00:00 EST 2019}

}

Copy to clipboard

Journal Article:

Free Publicly Available Full Text

Accepted Manuscript (Publisher)

Accepted Manuscript (DOE)

Publisher's Version of Record

https://doi.org/10.1016/j.apradiso.2019.108973

Other availability

Search WorldCat to find libraries that may hold this journal

Citation Metrics:

Cited by: 13 works

Citation information provided by
Web of Science

Save / Share:

Export Metadata

Save to My Library

Similar Records in DOE PAGES and OSTI.GOV collections:

Separation of Protactinium Employing Sulfur-Based Extraction Chromatographic Resins

Journal Article Mastren, Tara ; Stein, Benjamin W. ; Parker, T. Gannon ; ... - Analytical Chemistry

Protactinium-230 (t_1/2 = 17.4 d) is the parent isotope of ²³⁰U (t_1/2 = 20.8 d), a radionuclide of interest for targeted alpha therapy (TAT). Column chromatographic methods have been developed to separate no-carrier-added ²³⁰Pa from proton irradiated thorium targets and accompanying fission products. Results reported within this paper demonstrate the use of novel sulfur bearing chromatographic extraction resins for the selective separation of protactinium. The recovery yield of ²³⁰Pa was 93 ± 4% employing a R₃P=S type commercially available resin and 88 ± 4% employing a DGTA (diglycothioamide) containing custom synthesized extraction chromatographic resin. The radiochemical purity of the recoveredmore »« less
Cited by 15
https://doi.org/10.1021/acs.analchem.8b01380

Full Text Available
Measurement of cross sections for the {sup 232}Th(P,4n){sup 229}Pa reaction at low proton energies

Journal Article Jost, C. U. ; Griswold, J. R. ; Bruffey, S. H. ; ... - AIP Conference Proceedings

The alpha-emitters {sup 225}Ac and {sup 213}Bi are of great interest for alpha-radioimmunotherapy which uses radioisotopes attached to cancer-seeking antibodies to efficiently treat various types of cancers. Both radioisotopes are daughters of the long-lived {sup 229}Th(t{sub 1/2} = 7880y). {sup 229}Th can be produced by proton irradiation of {sup 232}Th and {sup 230}Th, either directly or through production of isobars that beta-decay into {sup 229}Th. To obtain excitation functions, {sup 232}Th and {sup 230}Th have been irradiated at the On-Line Test Facility at the Holifield Radioactive Ion Beam Facility at ORNL. Benchmark tests conducted with Cu and Ni foils showmore »« less
https://doi.org/10.1063/1.4802383
A reverse ²³⁰U/²²⁶Th radionuclide generator for targeted alpha therapy applications

Journal Article Mastren, Tara ; Akin, Andrew ; Copping, Roy ; ... - Nuclear Medicine and Biology

Thorium-226 (half-life 30.6 m) is a radionuclide of interest for use in targeted alpha therapy applications. Additionally, due to its short half-life, ²²⁶Th must be provided through a radionuclide generator system from its parent ²³⁰U (20.8 d). Furthermore, as the half-life of ²²⁶Th is very short, it should be provided in a form that is directly amenable to use in biomedical applications.
https://doi.org/10.1016/j.nucmedbio.2020.09.006

Full Text Available
Production of ${}^{229}{Th}$ for medical applications: Excitation functions of low-energy protons on ${}^{232}{Th}$ targets

Journal Article Griswold, Justin R. ; Jost, Carola U. ; Stracener, Daniel W. ; ... - Physical Review C

As a part of a general program to evaluate production routes for ²²⁹Th, we studied production of ²²⁹Th via proton-induced reactions on ²³²Th targets bombarded with low-energy protons, E_p ≤ 40MeV. The reported excitation functions include those for proton-induced reactions on natural thorium yielding to ^{228,229,230&232}Pa isotopes; ²³²Th(p,xn) reactions, where x=1, 3, 4, and 5, at proton energy ranges of 12–40 MeV. Although the data for ²³²Th(p,n)²²⁸Pa, ²³²Th(p,3n)²³⁰Pa, and ²³²Th(p,5n)²³²Pa reactions were deduced by direct analysis of the thorium foils after irradiation, the data for ²³²Th(p,4n)²²⁹Pa were obtained by radiochemical techniques. The half-life of ²²⁹Pa was evaluated and determined tomore »« less
Cited by 3
https://doi.org/10.1103/PhysRevC.98.044607

Full Text Available
Large scale accelerator production of ²²⁵Ac: Effective cross sections for 78–192 MeV protons incident on ²³²Th targets

Journal Article Griswold, J. R. ; Medvedev, D. G. ; Engle, J. W. ; ... - Applied Radiation and Isotopes

Actinium-225 and ²¹³Bi have been used successfully in targeted alpha therapy (TAT) in preclinical and clinical research. This paper is a continuation of research activities aiming to expand the availability of ²²⁵Ac. The high energy proton spallation reaction on natural thorium metal target has been utilized to produce millicurie quantities of ²²⁵Ac. The results of sixteen irradiation experiments of Th metal at beam energies between 78 and 200 MeV are summarized in this work. Irradiations have been conducted at Brookhaven National Laboratory (BNL) and Los Alamos National Laboratory (LANL), while target dissolution and processing was carried out at Oak Ridgemore »« less
Cited by 53
https://doi.org/10.1016/j.apradiso.2016.09.026

Full Text Available

Similar Records

Title: Production of 230Pa by proton irradiation of 232Th at the LANL isotope production facility: Precursor of 230U for targeted alpha therapy

Abstract

Citation Formats

Title: Production of ²³⁰Pa by proton irradiation of ²³²Th at the LANL isotope production facility: Precursor of ²³⁰U for targeted alpha therapy